Gene · 4261
Papers3,496
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 3,496
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Study of NLRC4 in Patients with Leprosy. | Indian J Dermatol | 2023 | 37822385 | PubTator, text mining | PubMed |
| Identification of IL-27 as a novel regulator of major histocompatibility complex class I and class II expression, antigen presentation, and processing in intestinal epithelial cells. | Front Immunol | 2023 | 37818353 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing reveals a peripheral landscape of immune cells in Schistosomiasis japonica. | Parasit Vectors | 2023 | 37817226 | PubTator, text mining | PubMed |
| Immune-epigenetic crosstalk in haematological malignancies. | Front Cell Dev Biol | 2023 | 37808081 | PubTator, text mining | PubMed |
| [Clinical characteristics and efficacy analysis of 11 patients with primary cutaneous diffuse large B-cell lymphoma, leg type]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37803847 | PubTator, text mining | PubMed |
| Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. | J Immunother Cancer | 2023 | 37802604 | PubTator, text mining | PubMed |
| The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition. | Front Immunol | 2023 | 37799721 | PubTator, text mining | PubMed |
| Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platform. | Mol Ther Nucleic Acids | 2023 | 37799328 | PubTator, text mining | PubMed |
| Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial Tumors. | JTO Clin Res Rep | 2023 | 37799325 | PubTator, text mining | PubMed |
| The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality. | Front Oncol | 2023 | 37795443 | PubTator, text mining | PubMed |
| Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia. | Front Immunol | 2023 | 37795087 | PubTator, text mining | PubMed |
| Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. | Cell | 2023 | 37794590 | PubTator, text mining | PubMed |
| PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity. | J Immunother Cancer | 2023 | 37793852 | PubTator, text mining | PubMed |
| Epstein-Barr virus infection: the micro and macro worlds. | Virol J | 2023 | 37784180 | PubTator, text mining | PubMed |
| Comprehensive analysis of ceRNA network composed of circRNA, miRNA, and mRNA in septic acute kidney injury patients based on RNA-seq. | Front Genet | 2023 | 37779910 | PubTator, text mining | PubMed |
| He protec but he also attac - Inflammasomes swinging the sword. | Biomed J | 2023 | 37777068 | PubTator, text mining | PubMed |
| Current perspective on biological properties of plasmacytoid dendritic cells and dysfunction in gut. | Immun Inflamm Dis | 2023 | 37773693 | PubTator, text mining | PubMed |
| Impact of Treatment with Ustekinumab on Severe Infections in a Patient with Uncontrolled Psoriasis and Late-Onset Combined Primary Immunodeficiency: Case Report. | Pathogens | 2023 | 37764964 | PubTator, text mining | PubMed |
| Introducing Molecular Chaperones into the Causality and Prospective Management of Autoimmune Hepatitis. | Dig Dis Sci | 2023 | 37755606 | PubTator, text mining | PubMed |
| Contribution of viral and bacterial infections to senescence and immunosenescence. | Front Cell Infect Microbiol | 2023 | 37753486 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4261/papers?page=15